The overall scientific goal of this ambitious program project is to develop highly innovative methods for cancer clinical trials that can hasten successful introduction of effective new therapies into practice. The method of approach is to leverage recent advances in statistical and computational science to create new clinical trial designs and data analysis tools that resolve many of the key scientific limitations of current clinical trial methodology. The projects focus on practical design and analysis problems in Phase II and Phase 111 clinical trials, the problem of missing data and efficient use of prognostic information, postmarketing surveillance and comparative effectiveness research using clinical trial data, pharmacogenetics and individualized therapies, and the potential of dynamic treatment regimens to improve cancer treatment. The proposed clinical trial design and analysis innovations have the potential to change the prevailing clinical trial paradigm and greatly increase the rate of discovery and translation of new treatments into clinical practice. Our multi-institutional approach includes an effective and energetic process for intense, coordinated implementation, communication and dissemination of results, including developing new software for practical implementation of the newly developed methods. Our comprehensive and novel approach will lead to significant improvements in cancer clinical trial practice that will result in improved health of cancer patients.

Public Health Relevance

The proposed program project aims to dramatically improve the efficiency of the cancer clinical trial process in order to improve the health and longevity of cancer patients. This is extremely important to public health since almost all biomedical advances in cancer treatment must pass through the clinical trial process before becoming accepted clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142538-05
Application #
8643480
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Wu, Roy S
Project Start
2010-04-01
Project End
2015-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Potthoff, Richard F (2018) Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results. J Biopharm Stat 28:633-644
Wang, Ting; Wang, Xiaofei; Zhou, Haibo et al. (2018) Auxiliary variable-enriched biomarker-stratified design. Stat Med 37:4610-4635
Hibbard, Jonathan C; Friedstat, Jonathan S; Thomas, Sonia M et al. (2018) LIBERTI: A SMART study in plastic surgery. Clin Trials 15:286-293
Burbank, Allison J; Todoric, Krista; Steele, Pamela et al. (2018) Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics. Respir Res 19:152
Urrutia, Eugene; Chen, Hao; Zhou, Zilu et al. (2018) Integrative pipeline for profiling DNA copy number and inferring tumor phylogeny. Bioinformatics 34:2126-2128
Chen, Jingxiang; Fu, Haoda; He, Xuanyao et al. (2018) Estimating individualized treatment rules for ordinal treatments. Biometrics 74:924-933
Luo, Yiwen; Maity, Arnab; Wu, Michael C et al. (2018) On the substructure controls in rare variant analysis: Principal components or variance components? Genet Epidemiol 42:276-287
Van den Berge, Koen; Perraudeau, Fanny; Soneson, Charlotte et al. (2018) Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications. Genome Biol 19:24
Yu-Feng Liu, Leo; Liu, Yufeng; Zhu, Hongtu et al. (2018) SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data. Neuroimage 175:230-245
Kong, Dehan; Maity, Arnab; Hsu, Fang-Chi et al. (2018) Rejoinder to ""A note on testing and estimation in marker-set association study using semiparametric quantile regression kernel machine"". Biometrics 74:767-768

Showing the most recent 10 out of 549 publications